{Reference Type}: Journal Article
{Title}: Landscape of targeted therapies for advanced urothelial carcinoma.
{Author}: Shang S;Zhang L;Liu K;Lv M;Zhang J;Ju D;Wei D;Sun Z;Wang P;Yuan J;Zhu Z;
{Journal}: Explor Target Antitumor Ther
{Volume}: 5
{Issue}: 3
{Year}: 2024
暂无{DOI}: 10.37349/etat.2024.00240
{Abstract}: Bladder cancer (BC) is the tenth most common malignancy globally. Urothelial carcinoma (UC) is a major type of BC, and advanced UC (aUC) is associated with poor clinical outcomes and limited survival rates. Current options for aUC treatment mainly include chemotherapy and immunotherapy. These options have moderate efficacy and modest impact on overall survival and thus highlight the need for novel therapeutic approaches. aUC patients harbor a high tumor mutation burden and abundant molecular alterations, which are the basis for targeted therapies. Erdafitinib is currently the only Food and Drug Administration (FDA)-approved targeted therapy for aUC. Many potential targeted therapeutics aiming at other molecular alterations are under investigation. This review summarizes the current understanding of molecular alterations associated with aUC targeted therapy. It also comprehensively discusses the related interventions for treatment in clinical research and the potential of using novel targeted drugs in combination therapy.